CCWM
PCVX icon

Cassaday & Co Wealth Management’s Vaxcyte PCVX Stock Holding History

Cassaday & Co Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117 Hold
2
– – ﹤0.01% 1258
2026
Q1 		$117 Buy
+2
New +$109 ﹤0.01% 1320

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Cassaday & Co Wealth Management's PCVX Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Vaxcyte (PCVX) position steady in Q2 2026 at 2 shares worth $117. The position accounts for ﹤0.01% of the portfolio, ranked #1258.

Cassaday & Co Wealth Management first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Cassaday & Co Wealth Management held 2 shares of Vaxcyte worth $117 as of Q2 2026.
  • Cassaday & Co Wealth Management left its Vaxcyte share count unchanged in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1258 holding.
  • Cassaday & Co Wealth Management first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.